MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$2,905,615
EPS
-$4.68
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Net loss
-
-
-2,646,172
-1,564,797.75
Deemed dividend arising from preferred stock and warrant down-round provision
867,796
1,586
0
21,901*
Loss on disposal of discontinued operations, net of tax
0
0
0
25,000
Gain (loss) from discontinued operations
0
0
0
-25,000*
(benefit from) provision for income taxes
0
0
35
1,583.5*
General and administrative
1,891,108
1,394,932
2,494,532
1,051,139.5*
Research and development
105,576
17,815
33,167
299,290.5*
Credit loss expense - short-term note receivable
-567,000
271,000
197,000
90,000*
Total expenses
1,429,684
1,683,747
2,724,699
1,440,430
Loss from operations
-1,429,684
-1,683,747
-2,724,699
-1,440,430*
Loss on change in fair value of derivative liabilities
0
0
0
47,767*
Loss on issuance of convertible debt
0
91,943
0
89,569.75*
Gain on change in fair value of warrant liabilities
-
15,974
39,224
103,952.5*
Gain on voluntary conversion of convertible debt into common stock
0
0
-
14,002.5*
Loss on monthly redemptions of convertible debt into common stock
0
0
0
52,213*
Gain on settlements of accounts payable
0
-
-
87,076.25*
Other income, net
0
-
-
486.5*
Loss (gain) on change in fair value of warrant liabilities
-148,346
-
-
-
Loss on change in fair value of convertible debt
-197,667
37,874
-
-14,249.25*
Interest expense
455,941
106,052
73,615
227,235.75*
Interest income
193,819
142,477
112,953
32,198.75*
Total other expense (income), net
-608,135
-1,670
78,562
-97,784.25*
Loss before (benefit from) provision for income taxes
-2,037,819
-1,685,417
-2,646,137
-1,538,214.25*
Net loss from continuing operations
-2,037,819
-1,685,417
-2,646,172
-1,539,797.75*
Net loss
-2,037,819
-1,685,417
-
-1,564,797.75*
Net loss attributable to qualigen therapeutics, inc
-2,905,615
-1,687,003
-2,646,172
-1,586,698.75
Basic EPS
-4.68
-1
-1.82
-4.388
Diluted EPS
-4.68
-1
-1.82
-4.388
Basic Average Shares
620,694
1,683,881
1,456,714
361,587
Diluted Average Shares
620,694
1,683,881
1,456,714
361,587
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to qualigen...
-$2,905,615
Net loss
-$2,037,819
Deemed dividend
arising from preferred...
$867,796
Net loss from
continuing operations
-$2,037,819
Loss before (benefit
from) provision for...
-$2,037,819
Loss from operations
-$1,429,684
Total other expense
(income), net
-$608,135
Interest income
$193,819
Total expenses
$1,429,684
Interest expense
$455,941
Loss on change in fair
value of convertible...
-$197,667
Credit loss expense -
short-term note receivable
-$567,000
Loss (gain) on change
in fair value of...
-$148,346
General and
administrative
$1,891,108
Research and development
$105,576
Buy us a coffee
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)